CClinicalTrials.gg
Not yet recruitingNCT07847307Updated Sep 29, 2026

ENDOBARIHEART STUDY

An interventional study of echocardiography and Coronary CT angiography in Obesity & Overweight, sponsored by Maria Cecilia Hospital. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Maria Cecilia Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary outcome of this study is to evaluate changes in cardiovascular risk after endoscopic sleeve gastroplasty (ESG) in patients at high cardiovascular risk, using the SCORE2 ( Systematic COronary Risk Evaluation 2) and SCORE2-OP ( Systematic COronary Risk Evaluation 2 Older Persons) risk scores, which estimate the risk of having a cardiovascular event.

Read the detailed description

This study aims to evaluate whether endoscopic sleeve gastroplasty (ESG), a minimally invasive procedure that reduces the size of the stomach, may improve cardiovascular health in patients with a high risk of cardiovascular disease.

Cardiovascular risk refers to the likelihood of developing serious conditions such as heart attack or stroke. In this study, cardiovascular risk will be assessed using two validated risk scores: SCORE2 (Systematic COronary Risk Evaluation 2), used mainly in adults aged 40-69 years, and SCORE2-OP (Systematic COronary Risk Evaluation 2 - Older Persons), used in people aged 70 years and older. Risk modifiers include coronary calcium score (CAC), coronary angiography and the socioeconomic status, as well as the presence of specific comorbidities. Following recent scientific evidence, circulating biomarkers as well as imaging biomarkers like epicardial fat (EAT) characterization, the quantification of oxidative stress and the composition and role of gut microbiota are proposed to stratify and personalize the calculation of Cardiovascular risk (CV) and therefore improve CV prognosis

02

Conditions studied

  • Obesity & Overweight

Keywords

  • Cardiovascular Risk
  • Cardiovascular Risk Factors
  • Endoscopic Sleeve Gastroplasty
  • Obesity
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • informed consent
  • obesity or overweight
  • atherosclerotic cardiovascular disease
  • type 1 or type 2 diabetes mellitus
  • hypercholesterolemia or severe dyslipidemia
  • evidence of subclinical atherosclerosis

Exclusion criteria

Exclusion Criteria:

  • chronic inflammatory diseases
  • active viral or bacterial infections
  • severe anaemia or severe coagulopathy
  • severe chronic kidney failure
  • active malignancy
  • anticoagulant therapy
  • chronic treatment with immunosuppressants/immunomodulators
  • pregnancy
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Patients Undergoing Endoscopic Sleeve Gastroplasty

    A total of 20 mL will be collected. Urine samples will be collected before Endoscopic Sleeve Gastroplasty and in sterile conditions. Imaging techniques will be performed before ESG procedure as well.

    Other: echocardiography · Radiation: Coronary CT angiography · Biological: blood analysis

Interventions

  • Otherechocardiography

    Echocardiography will be performed in each patient The following parameters will be assessed: systolic function, diastolic function, presence/absence of ventricular hypertrophy, left atrial volume indexed (LAVi), left atrial strain (LAS), valvular morphology and function, estimated intracardiac pressures

  • RadiationCoronary CT angiography

    Coronary CT angiography has a duration of 10-15 minutes per patient and requires the use of contrast

  • Biologicalblood analysis

    Blood count, liver and kidney function, coagulation assessment, C-reactive protein, glycaemic and lipidic profile

05

What researchers measure

Primary outcomes

  1. Quantification of the impact of endoscopic sleeve gastroplasty on Cardiovascular risk

    Time frame: From enrollment to the end of follow up at 12 months

06

Study locations

1 site
  • Maria Cecilia Hospital
    Cotignola, Ravenna 48033, Italy
    • Elisa Giacomini · Contact · egiacomini@gvmnet.it · +39 0545.217688
    • Margherita Tiezzi, MD · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07847307
Lead sponsor
Maria Cecilia Hospital
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Elisa Giacomini, PhD
Contact
egiacomini@gvmnet.it
+39 0545.217688

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion